Insilico teams up with Menarini for breast cancer KAT6 inhibitor
Menarini subsidiary Stemline will receive upfront and milestone payments, potentially worth more than $500m, along with royalties from sales.
Menarini subsidiary Stemline will receive upfront and milestone payments, potentially worth more than $500m, along with royalties from sales.
What's Your Reaction?
